What Is Oligometastatic Prostate Cancer?

Michael Fraser, Bridget Koontz, Urban Emmenegger, Gert De Meerleer, Vincent Khoo, Felix Feng, Niall M. Corcoran, Christopher M. Hovens, Phuoc T Tran, Piet Ost, Paul C. Boutros

Research output: Contribution to journalArticle

Abstract

Advanced prostate cancer patients can present with both widely metastatic or oligometastatic disease. Accumulating clinical evidence suggests that patients with oligometastatic disease have improved clinical responses from metastasis-directed therapy. This suggests that tumours that give rise to the oligometastatic state are distinct biologically and genetically from those that induce widely metastatic lesions. Detailed genomic analysis of the oligometastatic state will identify the molecular events that distinguish localised from metastatic disease, defining the molecular signatures of curability. The GAP6 consortium is well poised to address this question. Patient summary: In this report, we have reviewed the evidence that prostate cancer patients with only a small number of distant tumour deposits have cancers that are driven by genetic and biological changes, which are distinct from those tumours that readily spread to many distant sites. So far, the evidence is not clear cut; however, in-depth studies to answer this question are underway.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Neoplasms
Neoplasm Metastasis
Therapeutics

Keywords

  • Cancer genomics
  • Oligometastasis
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Fraser, M., Koontz, B., Emmenegger, U., De Meerleer, G., Khoo, V., Feng, F., ... Boutros, P. C. (Accepted/In press). What Is Oligometastatic Prostate Cancer? European Urology Focus. https://doi.org/10.1016/j.euf.2018.12.009

What Is Oligometastatic Prostate Cancer? / Fraser, Michael; Koontz, Bridget; Emmenegger, Urban; De Meerleer, Gert; Khoo, Vincent; Feng, Felix; Corcoran, Niall M.; Hovens, Christopher M.; Tran, Phuoc T; Ost, Piet; Boutros, Paul C.

In: European Urology Focus, 01.01.2019.

Research output: Contribution to journalArticle

Fraser, M, Koontz, B, Emmenegger, U, De Meerleer, G, Khoo, V, Feng, F, Corcoran, NM, Hovens, CM, Tran, PT, Ost, P & Boutros, PC 2019, 'What Is Oligometastatic Prostate Cancer?', European Urology Focus. https://doi.org/10.1016/j.euf.2018.12.009
Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F et al. What Is Oligometastatic Prostate Cancer? European Urology Focus. 2019 Jan 1. https://doi.org/10.1016/j.euf.2018.12.009
Fraser, Michael ; Koontz, Bridget ; Emmenegger, Urban ; De Meerleer, Gert ; Khoo, Vincent ; Feng, Felix ; Corcoran, Niall M. ; Hovens, Christopher M. ; Tran, Phuoc T ; Ost, Piet ; Boutros, Paul C. / What Is Oligometastatic Prostate Cancer?. In: European Urology Focus. 2019.
@article{ead6510a50a54a4488d9f3abd1c827c2,
title = "What Is Oligometastatic Prostate Cancer?",
abstract = "Advanced prostate cancer patients can present with both widely metastatic or oligometastatic disease. Accumulating clinical evidence suggests that patients with oligometastatic disease have improved clinical responses from metastasis-directed therapy. This suggests that tumours that give rise to the oligometastatic state are distinct biologically and genetically from those that induce widely metastatic lesions. Detailed genomic analysis of the oligometastatic state will identify the molecular events that distinguish localised from metastatic disease, defining the molecular signatures of curability. The GAP6 consortium is well poised to address this question. Patient summary: In this report, we have reviewed the evidence that prostate cancer patients with only a small number of distant tumour deposits have cancers that are driven by genetic and biological changes, which are distinct from those tumours that readily spread to many distant sites. So far, the evidence is not clear cut; however, in-depth studies to answer this question are underway.",
keywords = "Cancer genomics, Oligometastasis, Prostate cancer",
author = "Michael Fraser and Bridget Koontz and Urban Emmenegger and {De Meerleer}, Gert and Vincent Khoo and Felix Feng and Corcoran, {Niall M.} and Hovens, {Christopher M.} and Tran, {Phuoc T} and Piet Ost and Boutros, {Paul C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.euf.2018.12.009",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - What Is Oligometastatic Prostate Cancer?

AU - Fraser, Michael

AU - Koontz, Bridget

AU - Emmenegger, Urban

AU - De Meerleer, Gert

AU - Khoo, Vincent

AU - Feng, Felix

AU - Corcoran, Niall M.

AU - Hovens, Christopher M.

AU - Tran, Phuoc T

AU - Ost, Piet

AU - Boutros, Paul C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Advanced prostate cancer patients can present with both widely metastatic or oligometastatic disease. Accumulating clinical evidence suggests that patients with oligometastatic disease have improved clinical responses from metastasis-directed therapy. This suggests that tumours that give rise to the oligometastatic state are distinct biologically and genetically from those that induce widely metastatic lesions. Detailed genomic analysis of the oligometastatic state will identify the molecular events that distinguish localised from metastatic disease, defining the molecular signatures of curability. The GAP6 consortium is well poised to address this question. Patient summary: In this report, we have reviewed the evidence that prostate cancer patients with only a small number of distant tumour deposits have cancers that are driven by genetic and biological changes, which are distinct from those tumours that readily spread to many distant sites. So far, the evidence is not clear cut; however, in-depth studies to answer this question are underway.

AB - Advanced prostate cancer patients can present with both widely metastatic or oligometastatic disease. Accumulating clinical evidence suggests that patients with oligometastatic disease have improved clinical responses from metastasis-directed therapy. This suggests that tumours that give rise to the oligometastatic state are distinct biologically and genetically from those that induce widely metastatic lesions. Detailed genomic analysis of the oligometastatic state will identify the molecular events that distinguish localised from metastatic disease, defining the molecular signatures of curability. The GAP6 consortium is well poised to address this question. Patient summary: In this report, we have reviewed the evidence that prostate cancer patients with only a small number of distant tumour deposits have cancers that are driven by genetic and biological changes, which are distinct from those tumours that readily spread to many distant sites. So far, the evidence is not clear cut; however, in-depth studies to answer this question are underway.

KW - Cancer genomics

KW - Oligometastasis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85059782438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059782438&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2018.12.009

DO - 10.1016/j.euf.2018.12.009

M3 - Article

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -